Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. - Qin, Ya-Zhen; Jiang, Qian; Lai, Yue-Yun; Jiang, Hao; Shi, Hong-Xia; Zhao, Xiao-Su; Liu, Yan-Rong; Huang, Xiao-Jun (Leukemia & Lymphoma, 2017)